The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA-Reference-Cited by-同舟云学术

The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA

Published:2022-11 Issue:11 Volume:9 Page:e854-e861
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Kantarjian Hagop,Paul Shilpa,Thakkar Jigar,Jabbour Elias

Publisher

Elsevier BV

Subject

Hematology

Reference53 articles.

1. Chronic Lymphocytic Leukemia;Kantarjian,2022

2. Chronic myeloid leukemia;Kantarjian,2019

3. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring;Jabbour;Am J Hematol,2022

4. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017

5. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial;Cortes;Blood,2021

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost?;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Optimal frontline therapy of chronic myeloid leukemia today, and related musings;American Journal of Hematology;2024-08-02

3. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

4. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase;Cancer;2024-05-28

5. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia;International Journal of Hematology;2024-05-15